Previous studies reported that m6A regulators, including IGF2BP1, show a correlation with poor prognosis and advanced clinic grade in ovarian cancer, NSCLC, and GC.188, 189, 190, 191, 192, 193 IGF2BP1 is also significantly elevated in malignant melanomas, and its high expression is strongly correlated with metastasis and poor prognosis.194. This evidence concerns the gene IGF2BP1 and ovarian carcinoma.